Aachen-based Startup Company Protembis Successfully Closes $ 10 Million Series A Financing
The Managing Directors and founders of Protembis GmbH, Karl von Mangoldt and Conrad Rasmus, have successfully closed a Series A financing round in a structured process.
A syndicate consisting of the US listed medical technology company Abiomed Inc., the Seed Fonds III for the region of Aachen and Mönchengladbach GmbH & Co. KG, coparion GmbH & Co. KG, as well as renowned family offices and internationally experienced angel investors, has invested in the Aachen-based medical technology startup Protembis GmbH. The company is developing a novel and innovative cerebral protection system that is designed to minimize the risk of stroke and other neurological injury, particularly during catheter-based heart valve implantations. Protembis has raised a total of $ 10 million in an oversubscribed Series A financing round and expects to bring its product to market maturity with this round.
ProtEmbo Minimizes the Risk of Particle Migration to the Brain During Interventional Heart Procedures
Protembis has developed the "ProtEmbo Cerebral Protection System" – also called the "ProtEmbo" – to minimize the risk of stroke and other neurological injury in heart valve interventions. Nowadays, the calcified native aortic valve can be replaced by an artificial heart valve, which is advanced via a catheter into the left ventricle, i.e. to the site of the calcified native valve. This procedure is called transcatheter aortic valve implantation (also called "TAVI" or "TAVR"). The heart valve prosthesis is opened, presses the old and defective native valve against the vessel wall and thus takes over its function. TAVI is a quicker and less invasive procedure and is conducted while the heart is beating; it is associated with less pain and a shorter hospital stay than the alternative open-heart surgery.
In both methods, however, there is a risk that calcific debris from the native heart valve or aorta is detached and then migrates to the brain via the bloodstream, where it can cause stroke or other neurological complications. The drugs used before, during and shortly after the heart valve procedure do not provide complete protection against this risk.
"Literally every TAVI intervention leads to particle migration to the brain" says Karl von Mangoldt, co-managing director and co-founder of Protembis. "Recent clinical studies have shown that up to 9 percent of TAVI patients suffer a stroke" adds Conrad Rasmus, also co-managing director and co-founder of Protembis. The Protembis team wants to minimize this risk with its novel device. The ProtEmbo is a catheter-based filter device which is advanced intuitively, safely and quickly via the radial artery of the left arm before the start of a TAVI procedure and removed again at the end of the procedure in order to prevent the migration of particles to the brain. The permeable material of the filter covers all arteries leading to the brain while allowing free passage of blood cells and blocking even the smallest embolic particles. The filter is coated with heparin to prevent it from clotting during the procedure, as well as prevent thrombus formation on the filter surface. "Patient safety should always be our top priority.” says Dr. Thorsten Siess, Chief Technology Officer at Abiomed. “We see great potential in Protembis' technology to make TAVI neurologically safer and thus enable TAVI to be used in an even larger patient population".
High Market Potential
"We see enormous potential for Protembis in this rapidly growing market segment, due to the demographic development and the associated increase in the number of minimally invasive heart valve interventions – and concomitant cerebral protection procedures" says Markus Krückemeier, Managing Director of the management company of Seed Fonds III Aachen und Mönchengladbach. "The evidence for the clinical need and potential benefit of cerebral protection during TAVI has grown significantly in recent years – Protembis therefore addresses a strong clinical need" adds Dr. Sebastian Pünzeler, Investment Manager at coparion.
ProtEmbo Has Already Been Successfully Used in Human Studies
Protembis has already successfully demonstrated the initial safety and feasibility of the ProtEmbo in a first-in-human clinical study – the effectiveness of the technology was also shown. "We plan to conduct further clinical studies in renowned heart centers in Europe and the U.S.A. and want to bring the ProtEmbo to market as quickly as possible" says Oliver Schumacher, Chief Technology Officer at Protembis.
Karl von Mangoldt & Conrad Rasmus
+49 (0) 241 9903 3622
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Abu Dhabi to Host Interfaith Alliance For Safer Communities: Child Dignity in the Digital World Forum on 19 November17.11.2018 13:40 | Pressemelding
Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, the UAE will host the first edition of the Interfaith Alliance For Safer Communities Forum on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181117005008/en/ His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (Photo: AETOSWire) The forum will host 450 guests including religious leaders, NGOs and heads of industry to discuss ongoing social challenges and develop comprehensive solutions for protecting youth from cybercrime. The Interfaith Alliance For Safer Communities Forum is an expansion of the Child Dignity in the Digital World Congress which was held in October 2017 in the Vatican, an
Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 11:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r
Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 18:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)
Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33 | Pressemelding
Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55 | Pressemelding
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk